Stay updated on Gilteritinib vs Midostaurin in AML Clinical Trial
Sign up to get notified when there's something new on the Gilteritinib vs Midostaurin in AML Clinical Trial page.

Latest updates to the Gilteritinib vs Midostaurin in AML Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new revision entry (v3.4.2) was added to the Record History; the site-wide funding notice and the v3.4.1 revision entry were removed.SummaryDifference0.8%

- Check21 days agoChange DetectedA notice banner about a lapse in government funding was added to the page, and the revision tag changed from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check28 days agoChange DetectedGlossary visibility and color-coded legends (green for additions, red for deletions) have been added to the study record history, and the revision label updated from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check42 days agoChange DetectedThe record history shows a minor update: a new revision entry v3.3.4 has been added and v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedA new version entry 'Revision: v3.3.3' was added to the Study Record Versions list. The 'HHS Vulnerability Disclosure' link was removed from the footer.SummaryDifference0.2%

- Check85 days agoChange DetectedThe Study Record Versions list shows a new entry Revision: v3.3.2 and the previous Revision: v3.3.1 has been removed.SummaryDifference0.1%

Stay in the know with updates to Gilteritinib vs Midostaurin in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gilteritinib vs Midostaurin in AML Clinical Trial page.